
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated a strong financial performance with a revenue increase that surpassed consensus expectations and an upward revision of its guidance, indicating robust operational execution. The company is anticipated to sustain double-digit growth fueled by increased utilization of its light adjustable lenses (LDD) and an expanding installed base, as emphasized by management's strategic initiatives. Additionally, RxSight's improved gross margin guidance for 2025 reflects operational efficiencies and positions the company for potential upside through further market penetration and enhanced volume growth.
Bears say
RxSight Inc. is experiencing declining utilization rates and LDD placements, with a notable drop to 8.0 LALs per LDD in 3Q25, down from 8.7 in the prior quarter and 10.1 a year earlier, indicating challenges in customer adoption. Additionally, the company's revenue decreased by 14% year-over-year to $30.3 million, alongside a significant 68% year-over-year reduction in the placement of Light Delivery Devices (LDDs) in 2Q25, highlighting disappointing commercial execution. Furthermore, risks such as increased competition in the intraocular lens market, dependence on capital equipment for adoption, and potential dilutive financing could negatively impact future growth prospects.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares